A Randomized Phase III Study of Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) In High Risk Patients With Stage I Non-Small Cell Lung Cancer (NSCLC)

HUMAN CLINICAL TRIAL - CONFIDENTIAL Title A Randomized Phase III Study of Sublobar Resection (SR) versus Stereotactic Ablative Radiotherapy (SAbR) in High Risk Patients with Stage I Non-Small Cell Lung Cancer (NSCLC) – The STABLE-MATES Trial Methodology Pre-randomized trial- Patients will be screened and pre-randomized to either SR or SAbR. Informed consent will be obtained after patients are made aware of the randomized assignment. Despite pre-randomization prior to consent, patients maintain their right to accept or decline any/all study activities. Only consenting patients will be allowed to participate in study activities, including observation after either randomized treatments or observation after standard of care treatment, while those declining consent will be managed by their physician(s) off study. Anticipated duration of accrual is 3 years. Patients should continue to be followed a minimum of 5 years from end of therapy. Objectives Determine if SAbR improves survival over SR in High Risk Operable Stage I NSCLC